Eli Lilly's board announced a dividend of $1.73 per share for the fourth quarter of 2026, payable on December 10 to shareholders recorded by November 13. This dividend reflects the company's ongoing commitment to returning value to shareholders amid its efforts in advancing medical research and treatments. Investors can expect this payment as part of Lilly's strategy to support its financial health while continuing innovation in healthcare.
Eli Lilly's stock trades at USD 1,275.38 on Pluang as of October 26, 2026, 22:31 WIB, showing a modest 0.15% increase in one day. The company maintains a dividend yield of 0.54%, reflecting steady returns for shareholders. Its market capitalization stands at $1.14 trillion, underscoring its significant presence in the health sector.
Thermo Fisher Scientific reported 5% organic growth, surpassing consensus by 2 percentage points, prompting management to raise its full-year growth forecast. Mettler-Toledo's local-currency sales grew 6%, exceeding its previous 3% guidance. TEVA als...
Eli Lilly will report its Q3 2026 earnings on October 29, following five consecutive beats on earnings per share (EPS). The company showed strong revenue growth last quarter, driven by blockbuster drugs Mounjaro and Zepbound, with management raising ...
Eli Lilly's investigational drug sofetabart mipitecan (Sofe-M), combined with bevacizumab, achieved a 79% confirmed objective response rate and 100% disease control rate in a Phase 1 study involving platinum-sensitive ovarian cancer patients. The tre...
More than 200 companies are actively developing over 240 Alzheimer's disease therapies, with around 20 drugs in late-stage trials and many others in earlier phases. Key players include Eli Lilly, Biogen, Johnson & Johnson, and Eisai, focusing on inno...
